Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression
Salarius Pharmaceuticals, Inc. (SLRX)
Company Research
Source: GlobeNewswire
HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19th at 12pm Eastern Time. The call will feature a presentation by KOLs Damon Reed, MD, Moffitt Cancer Center, and Johnathan Whetstine, PhD, Fox Chase Cancer Center, who will discuss Epigenetics, and how drugs that regulate gene expression (“epigenetic drugs”) are a viable strategy for treatment and management of cancer. They will also discuss recent clinical successes with epigenetic drugs, and what to expect from novel agents. Drs. Reed and Whetstine will be available to answer questions at the conclusion of the call. The call will also feature a presentation by Salarius’ management team, which will provide an update on their lead program, Seclidemstat. Management will share the latest on their clinical program and
Show less
Read more
Impact Snapshot
Event Time:
SLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLRX alerts
High impacting Salarius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SLRX
News
- Lysine Specific Demethylase 1 Inhibitors Drug Pipeline Research 2024 [Yahoo! Finance]Yahoo! Finance
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses [Yahoo! Finance]Yahoo! Finance
- Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesGlobeNewswire
SLRX
Earnings
- 11/9/23 - Beat
SLRX
Sec Filings
- 4/22/24 - Form 10-K/A
- 4/12/24 - Form 4
- 3/26/24 - Form DEFA14A
- SLRX's page on the SEC website